Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study.

Tytuł:
Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study.
Autorzy:
Zeze K; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Hirano A; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Torisu T; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. .
Esaki M; Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Moriyama T; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Umeno J; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Kawasaki K; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Fujioka S; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Fuyuno Y; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Matsuno Y; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Kitazono T; Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Źródło:
Digestive diseases and sciences [Dig Dis Sci] 2021 Sep; Vol. 66 (9), pp. 3124-3131. Date of Electronic Publication: 2020 Sep 13.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2005- : New York, NY : Springer Science + Business Media
Original Publication: New York, Plenum Pub. Corp.
MeSH Terms:
Azathioprine*/administration & dosage
Azathioprine*/adverse effects
Crohn Disease*/diagnosis
Crohn Disease*/drug therapy
Crohn Disease*/epidemiology
Drug Therapy, Combination*/adverse effects
Drug Therapy, Combination*/methods
Drug-Related Side Effects and Adverse Reactions*/diagnosis
Drug-Related Side Effects and Adverse Reactions*/etiology
Infliximab*/administration & dosage
Infliximab*/adverse effects
Mercaptopurine*/administration & dosage
Mercaptopurine*/adverse effects
Adult ; Antimetabolites/administration & dosage ; Antimetabolites/adverse effects ; Biological Products/administration & dosage ; Biological Products/adverse effects ; Drug Monitoring/methods ; Drug Synergism ; Female ; Humans ; Japan/epidemiology ; Male ; Retrospective Studies ; Risk Assessment ; Treatment Outcome
References:
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741–1755. https://doi.org/10.1016/S0140-6736(16)31711-1 . (PMID: 10.1016/S0140-6736(16)31711-127914655)
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. https://doi.org/10.1016/S0140-6736(02)08512-4 . (PMID: 10.1016/S0140-6736(02)08512-412047962)
Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24–30. https://doi.org/10.1016/j.autrev.2013.06.002 . (PMID: 10.1016/j.autrev.2013.06.00223792214)
Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–1053. https://doi.org/10.1111/apt.14368 . (PMID: 10.1111/apt.1436829027257)
Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn’s disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010;16(11):1898–1904. https://doi.org/10.1002/ibd.21259 . (PMID: 10.1002/ibd.2125920310016)
Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol.. 2014;11(4):243–255. https://doi.org/10.1038/nrgastro.2013.253 . (PMID: 10.1038/nrgastro.2013.25324393836)
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135. https://doi.org/10.1038/ctg.2015.63 . (PMID: 10.1038/ctg.2015.63267410654737871)
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395. https://doi.org/10.1056/NEJMoa0904492 . (PMID: 10.1056/NEJMoa090449220393175)
Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1126–1135. https://doi.org/10.1111/apt.12733 . (PMID: 10.1111/apt.1273324689499)
Bots S, Gecse K, Barclay M, D’Haens G. Combination Immunosuppression in IBD. Inflamm Bowel Dis. 2018;24(3):539–545. https://doi.org/10.1093/ibd/izx065 . (PMID: 10.1093/ibd/izx06529462391)
Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–8 e1. https://doi.org/10.1053/j.gastro.2013.11.024 .
Moran GW, Dubeau MF, Kaplan GG, et al. Clinical predictors of thiopurine-related adverse events in Crohn’s disease. World J Gastroenterol. 2015;21(25):7795–7804. https://doi.org/10.3748/wjg.v21.i25.7795 . (PMID: 10.3748/wjg.v21.i25.7795261670794491966)
Calafat M, Manosa M, Canete F, et al. Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther. 2019;50(7):780–788. https://doi.org/10.1111/apt.15458 . (PMID: 10.1111/apt.1545831429097)
Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41 e1. https://doi.org/10.1016/j.cgh.2010.09.016 .
Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA. 2017;318(17):1679–1686. https://doi.org/10.1001/jama.2017.16071 . (PMID: 10.1001/jama.2017.16071291148325818785)
Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155(2):337–46 e10. https://doi.org/10.1053/j.gastro.2018.04.012 .
Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134(7):1861–1868. https://doi.org/10.1053/j.gastro.2008.03.004 . (PMID: 10.1053/j.gastro.2008.03.00418440315)
Bar-Yoseph H, Waterman M, Almog R, et al. Prevention of antidrug antibody formation to infliximab in Crohn’s patients with prior failure of thiopurines. Clin Gastroenterol Hepatol. 2017;15(1):69–75. https://doi.org/10.1016/j.cgh.2016.06.028 . (PMID: 10.1016/j.cgh.2016.06.02827404966)
Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. A role for thiopurine metabolites in the synergism between thiopurines and infliximab in inflammatory bowel disease. J Crohns Colitis.. 2018;12(3):298–305. https://doi.org/10.1093/ecco-jcc/jjx149 . (PMID: 10.1093/ecco-jcc/jjx14929145599)
Qiu Y, Mao R, Chen BL, Zhang SH, Guo J, He Y et al. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clin Gastroenterol Hepatol. 2017;15(9):1359–72 e6. https://doi.org/10.1016/j.cgh.2017.02.005 .
Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444–447. https://doi.org/10.1016/j.cgh.2012.10.020 . (PMID: 10.1016/j.cgh.2012.10.02023103905)
Ong DE, Kamm MA, Hartono JL, Lust M. Addition of thiopurines can recapture response in patients with Crohn’s disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol. 2013;28(10):1595–1599. https://doi.org/10.1111/jgh.12263 . (PMID: 10.1111/jgh.1226323662928)
Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000;43(10 Suppl):S85–S93. https://doi.org/10.1007/bf02237231 . (PMID: 10.1007/bf0223723111052483)
Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512. https://doi.org/10.1016/s0016-5107(04)01878-4 . (PMID: 10.1016/s0016-5107(04)01878-415472670)
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–963. https://doi.org/10.1016/0016-5085(90)90613-6 . (PMID: 10.1016/0016-5085(90)90613-62394349)
Costantino G, Furfaro F, Belvedere A, Alibrandi A, Fries W. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis.. 2012;6(5):588–596. https://doi.org/10.1016/j.crohns.2011.11.007 . (PMID: 10.1016/j.crohns.2011.11.00722398045)
van Gennep S, Konte K, Meijer B, et al. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. Aliment Pharmacol Ther. 2019;50(5):484–506. https://doi.org/10.1111/apt.15403 . (PMID: 10.1111/apt.1540331342537)
Roblin X, Boschetti G, Williet N, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017;46(2):142–149. https://doi.org/10.1111/apt.14106 . (PMID: 10.1111/apt.1410628449228)
Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D’Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1128–1134. https://doi.org/10.1111/apt.13994 . (PMID: 10.1111/apt.1399428230306)
Regueiro M, Feagan BG, Zou B, et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection. Gastroenterology. 2016;150(7):1568–1578. https://doi.org/10.1053/j.gastro.2016.02.072 . (PMID: 10.1053/j.gastro.2016.02.07226946343)
Sakuraba A, Okamoto S, Matsuoka K, et al. Combination therapy with infliximab and thiopurine compared to infliximab monotherapy in maintaining remission of postoperative Crohn’s disease. Digestion.. 2015;91(3):233–238. https://doi.org/10.1159/000375302 . (PMID: 10.1159/00037530225823572)
Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–373. https://doi.org/10.1038/ng.3508 . (PMID: 10.1038/ng.3508268787245029084)
Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017–1020. https://doi.org/10.1038/ng.3060 . (PMID: 10.1038/ng.3060251083854999337)
Kakuta Y, Naito T, Onodera M, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J.. 2016;16(3):280–285. https://doi.org/10.1038/tpj.2015.43 . (PMID: 10.1038/tpj.2015.4326076924)
Kakuta Y, Kawai Y, Okamoto D, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53(9):1065–1078. https://doi.org/10.1007/s00535-018-1486-7 . (PMID: 10.1007/s00535-018-1486-7299231226132901)
Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390–9 e1. https://doi.org/10.1053/j.gastro.2012.05.004 .
Contributed Indexing:
Keywords: Combination therapy; Crohn’s disease; Infliximab; Thiopurine
Substance Nomenclature:
0 (Antimetabolites)
0 (Biological Products)
B72HH48FLU (Infliximab)
E7WED276I5 (Mercaptopurine)
MRK240IY2L (Azathioprine)
Entry Date(s):
Date Created: 20200913 Date Completed: 20210929 Latest Revision: 20210929
Update Code:
20240105
DOI:
10.1007/s10620-020-06600-z
PMID:
32920717
Czasopismo naukowe
Background: Although combining thiopurine with infliximab (IFX) is considered to improve the clinical efficacy of IFX when treating Crohn's disease (CD), it also increases the risk of adverse events (AEs). We compared the efficacy and safety of delayed thiopurine addition after loss of response (LOR) to IFX with the efficacy and safety of an earlier combination of thiopurine and IFX.
Methods: This retrospective study analyzed patients with CD who started IFX as a first-line biologic at Kyushu University Hospital between June 2002 and July 2018. Patients were assigned to either the early-combination (EC) group, who started IFX and thiopurine simultaneously, or the late-combination (LC) group, who were treated with IFX alone until they developed LOR. We compared the cumulative IFX continuation rates and AE incidence between the two groups.
Results: One hundred seventy-six patients were enrolled in this study; 49 were enrolled in the EC group, and 127 were enrolled in the LC group. Disease activity at baseline did not significantly differ between the groups, nor did the cumulative IFX continuation rates differ between the groups (P = 0.30); however, the AE rate was significantly higher in the EC group than in the LC group (38.7% vs. 21.2%; P = 0.02). The severe AE rate was also higher in the EC group than in the LC group (18.3% vs 3.1%; P = 0.001).
Conclusion: Considering the risk-benefit balance, delayed addition of thiopurine after LOR to IFX might be an alternative strategy when using IFX to treat CD.
(© 2020. Springer Science+Business Media, LLC, part of Springer Nature.)
Comment in: Dig Dis Sci. 2021 Sep;66(9):2851-2852. (PMID: 33128112)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies